A coordinated HIV and sexually transmitted infection screening pathway for people who want clear answers after sexual exposure, a new partner, condom failure, symptoms or routine preventive screening. At STDtest.clinic, an appropriate package is built around the exposure date, the body sites involved, relevant medicines and the patient’s clinical needs—not simply the highest number of laboratory tests. Confidential consultation, eligible home or hotel specimen collection, laboratory processing, medical interpretation and follow-up can be coordinated where authorized and available.
What an HIV and STD test package actually includes
A useful combined package typically considers HIV, syphilis, chlamydia and gonorrhoea. Hepatitis B, hepatitis C and selected additional investigations are added when clinically indicated. HIV and syphilis generally require blood samples; genital chlamydia and gonorrhoea commonly use a first-catch urine sample or vaginal swab, while throat and rectal infections require specimens from those specific sites.
There is no single specimen that accurately screens every STI at every anatomical site. Nor is there a universal package that excludes all infections immediately after a sexual encounter. The published package must identify each organism, assay, specimen, anatomical site, price and any additional charge for extra-site swabs.
The clinic must insert its verified laboratory menu before publication. The tests discussed here are clinical options, not a claim that every assay is included in a currently sold package.
HIV fourth-generation antigen/antibody testing
A laboratory fourth-generation HIV-1/2 antigen/antibody test uses a venous blood sample to detect antibodies and HIV p24 antigen. The CDC describes a typical window of 18–45 days after exposure when antiretroviral medication has not altered detection. This is not a promise that a negative test at day 18 excludes infection.
For a person with no further exposure who has not taken PrEP or PEP, a negative laboratory antigen/antibody test after its applicable window is highly reassuring. An earlier negative may require repeat testing. Rapid finger-stick antigen/antibody assays have different windows and should not be treated as interchangeable with laboratory venous tests.
HIV RNA/NAT testing after a recent exposure
An HIV nucleic-acid test (NAT), sometimes called HIV RNA PCR, detects viral genetic material rather than the antibody response. CDC gives a typical 10–33-day detection window in people not taking antiretroviral medicines. NAT may be useful when very recent infection is suspected, symptoms suggest acute HIV, or screening results are discordant.
HIV RNA is not a blanket substitute for routine fourth-generation screening. It can be costly, may require confirmatory evaluation and cannot reliably exclude an exposure that happened only a few days earlier. Test selection and repeat timing should be clinician-led.
Urgent PEP assessment takes priority within 72 hours
If a possible substantial-risk HIV exposure occurred within the last 72 hours, seek urgent assessment immediately. Post-exposure prophylaxis (PEP) is a time-sensitive 28-day antiretroviral course. It should begin as soon as possible, ideally within 24 hours and generally no later than 72 hours. Do not wait for symptoms, a full STI panel, a home appointment or delayed laboratory results before obtaining emergency-capable assessment.
Baseline HIV testing and appropriate investigations are part of the PEP pathway, but indicated PEP should not be delayed while waiting for a test result. After PEP, HIV follow-up commonly includes laboratory antigen/antibody and diagnostic NAT testing at 4–6 weeks and 12 weeks after exposure under the CDC 2025 nPEP pathway; the clinician may tailor this based on circumstances and local protocols.
If home consultation and medicine access cannot occur promptly, attend an appropriate urgent or emergency service instead. Explore: PEP Dubai.
Chlamydia and gonorrhoea: choose the right specimen
Chlamydia trachomatis and Neisseria gonorrhoeae are commonly tested with nucleic-acid amplification tests (NAATs). For people with a penis, first-catch urine is frequently appropriate for urethral infection; a vaginal swab is often preferred for vaginal infection. After receptive oral sex, a throat swab may be indicated for gonorrhoea. After receptive anal exposure, rectal swabs may be required for chlamydia and gonorrhoea.
A negative urine test does not exclude an infection isolated to the throat or rectum. Tell the clinician about all exposure sites, even without symptoms. Some laboratories use validated combined chlamydia/gonorrhoea assays; patients should be told exactly what each swab covers.
These tests are often considered around 1–2 weeks after exposure, but this is a practical clinical interval, not a universally validated window or guarantee. If testing is performed earlier, symptoms develop or a partner tests positive, further evaluation may be needed.
Discharge, burning urination, pelvic pain, testicular pain, rectal pain or bleeding warrants assessment rather than relying only on an online package purchase.
Syphilis blood tests and interpretation
Syphilis screening usually involves a combination of treponemal and nontreponemal serology, according to the laboratory algorithm. Examples include an initial treponemal immunoassay with reflex RPR, or an RPR-based pathway with treponemal confirmation. A reactive result does not by itself tell the stage of infection or whether infection is newly acquired.
A person previously treated for syphilis can retain reactive treponemal antibodies for years. Quantitative RPR titres can help assess disease activity and treatment response in context. Early infection can produce negative blood tests, so a suspicious painless ulcer, rash or known contact needs clinical examination and possible repeat testing rather than false reassurance.
Hepatitis B and hepatitis C assessment
Hepatitis B evaluation can include HBsAg, anti-HBs and total anti-HBc to distinguish current infection, vaccine-associated immunity and evidence of previous infection. Additional tests such as HBV DNA or IgM anti-HBc depend on clinical findings. Vaccination history matters: someone without documented immunity may need hepatitis B vaccination, and selected recent exposures can require urgent post-exposure management.
Hepatitis C screening often begins with anti-HCV antibody and reflex HCV RNA if positive. HCV RNA may be considered earlier after a recent significant blood exposure. Hepatitis C is not routinely transmitted with the same efficiency through all sexual activities; testing decisions should reflect exposure details, risk factors and medical history.
A positive hepatitis screening result should trigger confirmatory interpretation and an appropriate liver-care pathway, not automatic inclusion of unverified medicines in the package.
Herpes, HPV, trichomonas and Mycoplasma genitalium
Herpes simplex virus (HSV): A fresh genital or oral lesion is best evaluated with a lesion swab for HSV NAAT/PCR where available. Routine HSV-2 antibody screening is not generally recommended for asymptomatic people, and IgM testing is not recommended.
Human papillomavirus (HPV): There is no general HPV blood test or universally useful screening test for all anatomical sites. Cervical HPV testing and cytology follow age- and risk-based screening pathways. Genital warts are often diagnosed clinically; HPV vaccination prevents certain future infections but does not treat existing disease.
Trichomonas vaginalis: NAAT may be appropriate for selected patients, especially those with relevant vaginal symptoms or risk.
Mycoplasma genitalium: Testing is generally targeted to persistent or recurrent urethritis/cervicitis and selected clinical situations, rather than included automatically in asymptomatic screening. Treatment can be complicated by antimicrobial resistance.
A package marketed as “12-in-1” or “full STD panel” must explain the clinical value and limitations of each included organism instead of implying that a larger list is always better.
Testing after different sexual exposures
After a broken condom: Review whether the exposure was vaginal, anal or oral, whether the source is known to have HIV, any confirmed sustained viral suppression, pregnancy risk and the exact date. HIV PEP urgency and bacterial STI sampling are separate decisions.
After oral sex: HIV risk is generally much lower than for receptive anal or vaginal intercourse, but throat gonorrhoea and other STIs may still be relevant. A throat swab is not replaced by urine screening.
After anal sex: Rectal chlamydia and gonorrhoea may be asymptomatic. HIV risk assessment may also be particularly important, depending on exposure type and source status.
After vaginal sex: Consider genital chlamydia/gonorrhoea NAAT, syphilis/HIV assessment as indicated, pregnancy testing where relevant and hepatitis B immunity.
After a partner reports an STI: Testing and, in some cases, presumptive treatment or partner management may be needed. Waiting for a routine panel is not always the correct response.
After sexual assault: Prompt emergency-capable medical assessment can address injuries, HIV PEP, hepatitis B protection, pregnancy prevention, forensic options and trauma-informed support. Do not delay this care for a package booking.
HIV symptoms and asymptomatic infection
Many people with HIV or another STI have no obvious symptoms. Acute HIV can sometimes cause fever, sore throat, rash, swollen lymph nodes, fatigue or other nonspecific symptoms, but these cannot diagnose HIV. Similarly, chlamydia, gonorrhoea and syphilis may be asymptomatic.
Persistent fever, new genital ulcers, abnormal discharge, pelvic pain or rectal symptoms should prompt a clinician-led assessment. Sudden severe testicular pain, severe pelvic or abdominal pain, fainting or systemic illness may require urgent facility-based care.
PrEP and PEP change HIV test interpretation
PrEP and PEP use can suppress viral replication or delay usual diagnostic markers, making a single early negative HIV test harder to interpret. Tell the clinician whether you have taken daily oral PrEP, event-driven PrEP, injectable PrEP or PEP, including the product, dates and missed doses.
People starting or continuing PrEP need the HIV testing pathway specified for their regimen. Recent long-acting PrEP use may require a different testing strategy. Do not assume a routine HIV package provides all tests needed for PrEP follow-up or that a negative rapid test is sufficient to restart medication.
When to book and when to repeat tests
The exposure date determines the plan. At a same-day consultation after a recent exposure, testing may establish baseline status but may not exclude infection acquired from that encounter. Chlamydia/gonorrhoea NAATs are commonly considered after an initial interval of roughly one to two weeks, with earlier testing or empiric management when symptoms or known contact justify it.
For HIV without antiretroviral use, CDC’s approximate detection windows are: NAT 10–33 days; laboratory venous antigen/antibody 18–45 days; rapid finger-stick antigen/antibody 18–90 days; antibody-only tests 23–90 days. These ranges are test-dependent and should not be treated as exact day-by-day guarantees.
Syphilis and hepatitis testing can require later repeat sampling because antibodies or other markers may not yet be detectable. The clinician should provide a personalised repeat-testing date and explain what each negative result does—and does not—exclude.
Home and hotel HIV + STD testing in Dubai
Selected specimens can be collected at a home, serviced apartment or hotel by an appropriately qualified healthcare professional where the service, laboratory and location are supported. A typical appointment may include a private history, venous blood collection, first-catch urine instructions and clinically appropriate self-collected or clinician-collected swabs.
The exact specimen pathway depends on the assay and laboratory validation. Some genital, throat or rectal swabs may require a clinic or a specially trained collector. Collection is performed at the visit; most HIV and STI assays are then analysed at a laboratory, not instantaneously in the hotel room.
The team should confirm patient identification, consent, specimen labelling, transport, anticipated result time, privacy process and any extra fees before the visit. A request for urgent PEP assessment should not be held until a convenient home appointment.
How a combined HIV and STD appointment works
- Confidential booking: Share your preferred location, symptoms, exposure date, whether you need urgent PEP assessment and any PrEP/PEP history.
- Clinical review: The doctor identifies exposed anatomical sites, pregnancy possibility, vaccination status, allergies and the most useful tests.
- Transparent test selection: The patient receives a clear list of assays, specimen types, laboratory processing, package price and any additional swab or consultation charges.
- Collection and analysis: A qualified professional obtains eligible samples and sends them through the validated laboratory pathway.
- Results and interpretation: A clinician explains reactive, negative, equivocal or discordant findings and whether repeat or confirmatory testing is needed.
- Treatment and prevention: Where clinically appropriate and authorized, the clinic coordinates prescriptions, eligible medicine supply, partner advice, vaccination, PrEP or PEP referral, and specialist care.
Understanding negative, reactive and positive results
Negative: The assay did not detect the target at the time of sampling. It may not exclude very recent infection, a different exposed site or an organism that was not included.
Reactive HIV screening: This is not by itself a final diagnosis. A laboratory diagnostic algorithm generally uses an HIV-1/HIV-2 antibody differentiation assay and, in selected cases, HIV-1 NAT. A clinician should coordinate confirmatory testing promptly.
Positive chlamydia/gonorrhoea NAAT: Usually supports targeted treatment and partner management. Site, pregnancy and allergy history matter.
Reactive syphilis serology: Needs interpretation of treponemal and nontreponemal results, past treatment and clinical stage.
Equivocal or unexpected results: May require repeat sampling, another assay or specialist review. No test result should be interpreted without its specimen, timing and clinical context.
Treatment after an STI diagnosis
Chlamydia: For uncomplicated infection in nonpregnant adults, CDC guidance commonly recommends doxycycline 100 mg orally twice daily for seven days; pregnancy requires a different approach, commonly azithromycin 1 g orally once, with follow-up as indicated.
Gonorrhoea: CDC guidance for uncomplicated infection commonly recommends ceftriaxone 500 mg intramuscularly once for people weighing under 150 kg, or 1 g at 150 kg or more; add chlamydia treatment when it has not been excluded. Local resistance and prescribing guidance must be considered.
Syphilis: Early syphilis is often treated with benzathine penicillin G 2.4 million units intramuscularly once; late latent syphilis or unknown duration generally requires weekly doses for three weeks. Stage, pregnancy and neurologic/ocular symptoms alter management.
HIV: A confirmed diagnosis requires prompt linkage to specialist antiretroviral treatment, not a generic antibiotic or a PrEP-only prescription.
Herpes and hepatitis: These require diagnosis-specific antiviral management or referral. Vaccines help prevent selected infections but do not cure an existing infection.
These are guideline examples, not an automatic prescription or a claim of clinic stock. The treating professional must assess diagnosis, contraindications, pregnancy, allergies, resistance, drug interactions and applicable UAE requirements.
Partners, reinfection and follow-up
STI management can include partner notification, abstaining from sex for the recommended interval, partner evaluation and follow-up testing. For chlamydia and gonorrhoea, reinfection is common; CDC generally recommends retesting approximately three months after treatment. Gonorrhoea at the pharynx generally requires a test of cure 7–14 days after treatment.
A positive result should be communicated without blame. The care plan may include condoms, hepatitis B or HPV vaccination, PrEP assessment, HIV testing at the correct interval and symptom review. Confidentiality does not remove applicable public-health reporting duties.
Testing during pregnancy and when planning pregnancy
Pregnancy changes the interpretation and treatment of several STIs. HIV and syphilis screening are important in antenatal care; chlamydia, gonorrhoea and hepatitis screening may also be indicated depending on recommendations and risk. Untreated infections can affect maternal and infant health.
Some antibiotics used outside pregnancy are not appropriate during pregnancy. A patient who is pregnant or may be pregnant should disclose this before specimens are collected or treatment is prescribed. Urgent symptoms or a reactive result should be reviewed by the relevant obstetric and infectious-disease team.
Confidentiality and result delivery
A home visit can reduce travel and offer a private setting, but confidential does not mean anonymous. Healthcare professionals may need to verify identity, create clinical records, use a licensed laboratory and comply with UAE public-health reporting obligations.
Before booking, patients can ask who will collect samples, how results are delivered, whether a doctor review is included, how long records are retained and which services require referral. The final website should link to the clinic’s approved privacy notice and verified licensing details.
Dubai, Abu Dhabi, Sharjah and UAE enquiries
STDtest.clinic is based in Arjan, Dubai. Patients may enquire about home or hotel collection in Dubai Marina, JBR, JLT, Palm Jumeirah, Downtown Dubai, Business Bay, DIFC, Jumeirah, Umm Suqeim, Al Barsha, Dubai Hills Estate, Emirates Hills, Arabian Ranches, Bluewaters, City Walk and Dubai Creek Harbour.
Enquiries from Abu Dhabi may include Saadiyat Island, Al Reem Island, Al Maryah Island, Yas Island, Al Raha Beach and Khalifa City; Sharjah enquiries may include Al Majaz, Al Khan, Al Taawun, Muwaileh and Aljada. Other emirates may request availability information.
These are enquiry areas, not a promise of coverage. Actual availability depends on the specific licence, emirate, clinician, laboratory collection pathway and appointment schedule.
Choose a package that answers your question
A combined HIV and STD package is most valuable when it produces an actionable clinical answer: which infections were tested, at which body sites, how reliable the timing was, what the results mean and whether anything needs repeating. Patients should be able to request a clear itemised test menu before payment.
Medical information and publishing verification
This content is educational and does not replace individual diagnosis or urgent medical care. Treatment decisions and laboratory interpretation require a qualified clinician. HIV PEP is time-sensitive; seek urgent care immediately after a potentially significant exposure within 72 hours.